RLYB331
Iron Overload-Disorders
Many patients with severe anemias experience ineffective erythropoiesis (red blood cell production) and iron overload, which are inadequately treated by the current standard of care. Significant morbidity and mortality can result, including multiorgan damage.
RLYB331
- Stage
- Preclinical
- Indication
- Anemia associated with iron overload disorders
- Therapeutic Modality
- Hematology
- Mechanism of Action
- Inhibitor of Matriptase-2 (MTP-2)
Matriptase 2 (MTP-2) Inhibitor Stage of Development
Preclinical
Potential Indications
Disorders associated with ineffective erythropoiesis and iron overload.
Disease Mechanism
MTP-2 reduces levels of hepcidin, a key protein regulator of iron in the circulation
Therapeutic Modality
Monoclonal antibody selectively targeting MTP-2
Mechanism of Action
Inhibition of MTP-2 to increase levels of hepcidin
Mode of Administration
Subcutaneous administration
MTP-2 inhibitor
RLYB331 is a potential, first-in-class MAb inhibitor of MTP-2, a serine protease that plays a critical role in hepcidin formation. The mechanism of action supports development for the treatment of iron overload and ineffective erythropoiesis associated disorders such as polycythemia vera, beta thalassemia and a subset of myelodysplastic syndromes.
This candidate has the potential to address unmet needs by reducing red blood cell transfusion requirements, ameliorating iron overload and ineffective erythropoiesis.
Non-clinical activities are underway to support transition into clinical development. There is potential to develop RLYB331 in multiple indications.